Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening

European Journal of Endocrinology

Volumn 155, Issue 1, 2006, Pages 33-39

  Hagström, Emil ^a   Lundgren, Ewa ^a   Rastad, Jonas ^a,b   Hellman, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MASS SCREENING; METABOLIC DISORDER; PARATHYROID ADENOMA; PARATHYROIDECTOMY; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADENOMA; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CALCIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM; LIPIDS; LIPOPROTEINS; MASS SCREENING; MIDDLE AGED; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 33746304220     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02173     Document Type: Article

References (43)

1. Hedbäck G & Odén A. Death risk factor analysis in primary hyperparathyroidism. European Journal of Clinical Investigation 1998 28 1011-1018.
2. Hedbäck G & Odén A. Increased risk of death from primary hyperparathyroidism - an update. European Journal of Clinical Investigation 1998 28 271-276.
3. Hagström E, Lundgren B, Lithell H, Berglund L, Ljunghall S, Hellman P & Rastad J. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clinical Endocrinolology (Oxf) 2002 56 253-260.
4. Valdemarsson S, Lindblom P & Bergenfelz A. Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. Journal of Internal Medicine 1998 244 241-249.
5. Ljunghall S, Lithell H, Vessby B & Wide L. Glucose and lipoprotein metabolism in primary hyperparathyroidism. Effects of parathyroidectomy. Acta Endocrinologica (Copenhagen) 1978 89 580-589.
6. Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N & Borretta G. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabetes Medicine 2002 19 958-961.
7. Ljunghall S, Palmér M, Åkerström G & Wide L. Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy. European Journal of Clinical Investigation 1983 13 373-377.
8. Taylor WH & Khaleeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes/Metabolism Research and Reviews 2001 17 175-180.
9. Bolland MJ, Grey AB, Gamble GD & Reid JR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 1525-1530.
10. Hagström E, Lundgren E, Mallmin H, Rastad J & Hellman P. Positive effect of parathyroidectomy on bone mineral density in mild asymptomatic primary hyperparathyroidism. Journal of Internal Medicine 2006 259 191-198.
11. Lacour B, Roullet JB, Liagre AM, Jorgetti V, Beyne P, Dubost C & Drueke T. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. American Journal of Kidney Diseases 1986 8 422-429.
12. Christensson T & Einarsson K. Serum lipids before and after parathyroidectomy in patients with primary hyperparathyroidism. Clinica Chimica Acta 1977 78 411-415.
13. Silverberg SJ, Shane E, Jacobs TP, Siris E & Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New England Journal of Medicine 1999 341 1249-1255.
14. Sitges-Serra A, Girvent M, Pereira JA, Jimeno J, Nogues X, Cano FJ & Sancho JJ. Bone mineral density in menopausal women with primary hyperparathyroidism before and after parathyroidectomy. World Journal of Surgery 2004 28 1148-1152.
15. Monchik J. Normocalcemic hyperparathyroidism. In Textbook of Endocrine Surgery, p 424. Eds O Clark, Q Duh & E Kebebew. San Francisco: WB Saunders, 2005.
16. Tordjman KM, Greenman Y, Osher E, Shenkerman G & Stern N. Characterization of normocalcemic primary hyperparathyroidism. American Journal of Medicine 2004 117 861-863.
17. Monchik JM & Gorgun E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery 2004 136 1242-1246.
18. Hagag P, Revet-Zak I, Hod N, Horne T, Rapoport MJ & Weiss M. Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test. Journal of Endocrinological Investigation 2003 26 327-332.
19. Maruani G, Hertig A, Paillard M & Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. Journal of Clinical Endocrinology and Metabolism 2003 88 4641-4648.
20. Lundgren E, Rastad J, Thurfjell E, Åkerström G & Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997 121 287-294.
21. Lundgren E, Ljunghall S, Åkerström G, Hetta J, Mallmin H & Rastad J. Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Surgery 1998 124 980-985.
22. Benson L, Ljunghall S, Groth T, Falk H, Hvarfner A, Rastad J, Wide L, & Akerstrom G. Optimal discrimination of mild hyperparathyroidism with total serum calcium, ionized calcium and parathyroid hormone measurements. Upsala Journal of Medical Sciences 1987 92 147-176.
23. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988 37 1595-1607.
24. Resnick L. The cellular ionic basis of hypertension and allied clinical conditions. Progress in Cardiovascular Diseases 1999 42 1-22.
25. Levy J. Abnormal cell calcium homeostasis in type 2 diabetes mellitus: a new look on old disease. Endocrine 1999 10 1-6.
26. Grey A & Reid I. Body weight and bone mineral density in hyperparathyroidism. Annals of Internal Medicine 1995 123 732.
27. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R & Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 1267-1278
28. NIH. Consensus development conference statement. Journal of Bone and Mineral Research 1991 6 S9-S13.
29. Bilezikian JP, Potts JT Jr, Fuleihan Gel H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R & Wells SA. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism 2002 87 5353-5361.
30. Prager R, Schernthaner G, Niederle B & Roka R. Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyroidism before and after surgery. Calcified Tissue International 1990 46 1-4.
31. Taylor WH & Khaleeli AA. Prevalence of primary hyperparathyroidism in patients with diabetes mellitus. Diabetes Medicine 1997 14 386-389.
32. Kumar S, Olukoga AO, Gordon C, Mawer EB, France M, Hosker JP, Davies M & Boulton AJ. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clinical Endocrinology (Oxford) 1994 40 47-53.
33. Almqvist EG, Bondeson AG, Bondeson L, Nissborg A, Smedgard P & Svensson SE. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002 132 1126-1132; discussion 1132.
34. Lundgren E, Lind L, Palmer M, Jakobsson S, Ljunghall S & Rastad J. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 2001 130 978-985.
35. Smith JC, Page MD, John R, Wheeler MH, Cockcroft JR, Scanlon MF & Davies JS. Augmentation of central arterial pressure in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 3515-3519.
36. Jorde R, Sundsfjord J, Fitzgerald P & Bonaa KH. Serum calcium and cardiovascular risk factors and diseases: the Tromsö study. Hypertension 1999 34 484-490.
37. Jorde R, Bonaa KH & Sundsfjord J. Population based study on serum ionised calcium, serum parathyroid hormone, and blood pressure. The Tromsö study. European Journal of Endocrinology 1999 141 350-357.
38. Palmér M, Adami HO, Bergstrom R, Jakobsson S, Åkerström G & Ljunghall S. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet 1987 1 59-62.
39. Leifsson BG & Ahrén B. Serum calcium and survival in a large health screening program. Journal of Clinical Endocrinology and Metabolism 1996 81 2149-2153.
40. Lind L, Skarfors E, Berglund L, Lithell H & Ljunghall S. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. Journal of Clinical Epidemiology 1997 50 967-973.
41. Silverberg SJ & Bilezikian JP. "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. Journal of Clinical Endocrinology and Metabolism 2003 88 5348-5352.
42. Rao DS, Wilson RJ, Kleerekoper M & Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. Journal of Clinical Endocrinology and Metabolism 1988 67 1294-1298.
43. NCEP. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of American Medical Association 2001 285 2486-2497.